Precision BioSciences (DTIL) Competitors $4.34 -0.01 (-0.12%) As of 12:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. EPRX, ENGN, TLSA, CTMX, OGI, GNFT, FDMT, IPHA, VTYX, and DERMShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Tiziana Life Sciences (TLSA), CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Its Competitors Eupraxia Pharmaceuticals enGene Tiziana Life Sciences CytomX Therapeutics Organigram Global GENFIT 4D Molecular Therapeutics Innate Pharma Ventyx Biosciences Journey Medical Precision BioSciences (NASDAQ:DTIL) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings. Do analysts rate DTIL or EPRX? Precision BioSciences currently has a consensus price target of $47.00, indicating a potential upside of 984.20%. Eupraxia Pharmaceuticals has a consensus price target of $11.00, indicating a potential upside of 102.21%. Given Precision BioSciences' higher possible upside, research analysts clearly believe Precision BioSciences is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do institutionals and insiders believe in DTIL or EPRX? 38.0% of Precision BioSciences shares are owned by institutional investors. 4.0% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, DTIL or EPRX? Precision BioSciences has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.70$7.17M-$2.01-2.16Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.16 Does the media favor DTIL or EPRX? In the previous week, Precision BioSciences and Precision BioSciences both had 2 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.14 beat Precision BioSciences' score of 0.12 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Precision BioSciences Neutral Eupraxia Pharmaceuticals Positive Which has more risk and volatility, DTIL or EPRX? Precision BioSciences has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Is DTIL or EPRX more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Precision BioSciences' net margin of -42.99%. Precision BioSciences' return on equity of -69.26% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences-42.99% -69.26% -29.30% Eupraxia Pharmaceuticals N/A -367.73%-112.23% SummaryPrecision BioSciences beats Eupraxia Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.08M$2.88B$5.48B$8.96BDividend YieldN/A2.44%5.22%4.00%P/E Ratio-2.1621.1127.4720.11Price / Sales0.70291.21429.10116.97Price / CashN/A41.7026.2128.59Price / Book0.637.447.965.59Net Income$7.17M-$55.14M$3.17B$248.65M7 Day Performance3.21%4.09%4.61%7.54%1 Month Performance-21.04%0.79%2.78%8.47%1 Year Performance-52.88%4.95%35.48%21.79% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.5046 of 5 stars$4.34-0.1%$47.00+984.2%-52.4%$48.08M$68.70M-2.16200EPRXEupraxia Pharmaceuticals2.4579 of 5 stars$5.76+8.7%$11.00+91.0%+117.3%$190.57MN/A-7.5829Gap UpHigh Trading VolumeENGNenGene2.7791 of 5 stars$3.64-0.5%$23.29+539.7%-57.6%$187.04MN/A-2.2131TLSATiziana Life Sciences0.6703 of 5 stars$1.58-1.3%N/A+85.5%$186.96MN/A0.008Positive NewsCTMXCytomX Therapeutics3.8444 of 5 stars$2.27+0.9%$5.33+134.9%+93.0%$181.40M$138.10M4.73170OGIOrganigram Global0.5318 of 5 stars$1.35flatN/A-10.4%$180.82M$117.47M13.50860GNFTGENFIT1.9781 of 5 stars$3.73+3.2%$13.00+249.0%-8.2%$180.49M$67.00M0.00120Positive NewsGap UpFDMT4D Molecular Therapeutics2.2772 of 5 stars$3.71-3.4%$29.56+696.6%-80.6%$177.89M$40K-1.17120IPHAInnate Pharma2.5278 of 5 stars$1.82-1.9%$11.00+506.1%-8.5%$170.53M$21.77M0.00220VTYXVentyx Biosciences2.3768 of 5 stars$2.14-8.5%$10.00+367.3%-3.5%$166.52MN/A-1.2230DERMJourney Medical1.918 of 5 stars$7.18+0.6%$9.50+32.3%+36.3%$166.33M$56.13M-18.4190Analyst Downgrade Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Alternatives enGene Alternatives Tiziana Life Sciences Alternatives CytomX Therapeutics Alternatives Organigram Global Alternatives GENFIT Alternatives 4D Molecular Therapeutics Alternatives Innate Pharma Alternatives Ventyx Biosciences Alternatives Journey Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
